NEW YORK (GenomeWeb News) – Hologic today announced the Netherlands Society for Pathology has approved the use of the Hologic Cervista HPV HR test in the Dutch national cervical screening program.

The National Institute for Public Health and the Environment in the Netherlands suggests routine pap testing and HPV HR triage for the ASCUS/LSIL (or atypical squamous cells of undetermined significance/ low-grade squamous intraepithelial lesion) testing for women over the age of 30 in order to identify those most likely to develop cervical cancer, Hologic said.